Document is current
Any future updates will be listed below
-
Authors
Gibson, Christopher
Wang, Shirley C.
Phoon, Arcturus
Thalanki Anantha, Nayana
Ottolino-Perry, Kathryn
Petropoulos, Stephen
Qureshi, Zuha
Subramanian, Vasanth
Shahid, Anam
O’Brien, Cristiana
Carcone, Steven
Chung, Suzanne
Tsui, Teresa
Son, Viktor
Sukhram, Mayleen
Meng, Fannong
Done, Susan J.
Easson, Alexandra M.
Cil, Tulin
Reedijk, Michael
Leong, Wey L.
DaCosta, Ralph S.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Canadian Institutes of Health Research
Canadian Institutes of Health Research
Canadian Institutes of Health Research
Canadian Institutes of Health Research
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 19 April 2024
First Online: 1 June 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the UHN Research Ethics Board (protocol code 10-0633) and the MSH Research Ethics Board (protocol code 13-0155E). Informed consent was obtained from all subjects involved in the study.
: Not applicable.
: RSD, KOP, CG, NTA, WLL, AME, and SJD are co-inventors on IP licensed to MolecuLight Inc. (Toronto, Canada) and photonamic GmbH & Co. KG (Pinneberg, Germany) commercializing this technology. These individuals were not involved with participant recruitment. This study was a UHN investigator-sponsored trial (clinicaltrials.gov identifier NCT01837225) prior to IP licensing. RSD is the Founder, Chief Scientific Officer, Board member, and Shareholder of MolecuLight Inc. MolecuLight staff were not involved directly or indirectly with this study. RSD participated in the conception and design of the study, and reviewed and edited the final manuscript. He did not recruit nor consent patients, nor collect, nor analyze data resulting from the study. 5-ALA HCl was provided by photonamic GmbH and Co. KG (Pinneberg, Germany) governed by a Drug Transfer Agreement between UHN and photonamic. RSD is the Chief Executive Officer of and holds interest in photonamic GmbH & Co. KG’s subsidiary company (SBI ALApharma Canada Inc., Toronto, Canada) developing this technology for commercialization. RSD’s potential conflicts of interest are governed by a UHN Conflict of Interest Management Plan. At the time of publishing, KOP is employed by and holds an interest in SBI ALApharma Canada Inc., however, was wholly employed by UHN with no COI at the time of her contributions to this study. All other authors declare that they have no competing interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
